Compare Enveric Biosciences Inc (ENVB) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Oxford Lane Capital Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Oxford Lane Capital Corp trades at $8.62 (market cap $829.34M). The key difference: Oxford Lane Capital Corp is far larger — about 124× Enveric Biosciences Inc's market cap, and Oxford Lane Capital Corp pays a 28.37% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Oxford Lane Capital Corp for 49 Days on average.
| ENVB | OXLC | |
|---|---|---|
Market Cap | $6.69M | $829.34M |
Volume | 41,141 | 1,709,917 |
Sector | Health | Financials |
52-Week High | $10.80 | $16.74 |
52-Week Low | $1.27 | $8.15 |
Typical Hold Time | 14 Days | 49 Days |
Enterprise Value | -$1.60M | $1.22B |
Dividend Yield | — | 28.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
OXLC trades at $8.46, down 2.53% on the day, with a bearish technical outlook and negative profitability metrics. Recent earnings misses and a sharp decline in net income for 2026 highlight fundamental challenges, though the stock pays consistent dividends. Analyst sentiment is mixed, with a 50% buy rating but cautious media coverage on sustainability.
The outlook remains risky due to volatile earnings, high payout ratios, and NAV erosion. Potential exists for value investors attracted by the P/B discount and high yield, but significant headwinds in CLO market exposure and operational cash flow deficits warrant caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
